Related Experiment Video
Updated: Jul 11, 2025

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
ANCA-associated vasculitis-treatment standard
Aglaia Chalkia1,2, David Jayne1
1Department of Medicine, University of Cambridge, Cambridge, UK.
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) treatment has evolved, improving outcomes but increasing toxicities. Recent trials focus on newer agents like avacopan and rituximab to optimize care and minimize adverse effects.
Area of Science:
- Rheumatology
- Immunology
- Internal Medicine
Background:
- Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are severe small-vessel inflammatory diseases.
- Historically fatal, AAV treatment transformed it into a relapsing/remitting condition with significant drug toxicities and organ damage.
Purpose of the Study:
- To review recent clinical trial evidence on AAV treatments.
- To interpret this evidence in the context of the 2022 European League of Associations of Rheumatology (EULAR) management recommendations.
- To focus on optimizing treatment and minimizing adverse effects.
Main Methods:
- Review of recent clinical trial data.
- Analysis of glucocorticoids, avacopan, plasma exchange, rituximab, and mepolizumab efficacy and safety.
- Interpretation of findings within the 2022 EULAR guidelines.
Main Results:
- Established treatments (glucocorticoids, cyclophosphamide) were optimized through trials.
- Newer targeted therapies (B-cell depletion, complement inhibition, IL-5 inhibition) show promise for specific AAV subtypes.
- Recent trials highlight the roles of avacopan, rituximab, and mepolizumab, alongside traditional therapies like plasma exchange.
Conclusions:
- Treatment advances have improved AAV outcomes but necessitate careful management of toxicities.
- Emerging therapies offer targeted approaches for granulomatosis with polyangiitis, microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis.
- Current research emphasizes minimizing treatment-related harm and understanding comorbidities in AAV management.
More Related Videos
10:09Drug Treatment by Central Venous Catheter in a Mouse Model of Angiotensin II Induced Abdominal Aortic Aneurysm and Monitoring by 3D Ultrasound
Published on: August 4, 2022
09:16Supervised Machine Learning for Semi-Quantification of Extracellular DNA in Glomerulonephritis
Published on: June 18, 2020
Related Concept Videos
Peripheral Artery Disease III: Interprofessional Care
Aneurysm III: Interprofessional Care
Venous Thrombosis III: Interprofessional Care
Nephrotic Syndrome II : Assessment and Medical Management
Drugs for Treatment of Ulcerative Colitis in IBD
Nephrotic Syndrome III : Nursing Management